AltPep Strengthens Advisory Board with Three Leading Experts in Alzheimer’s Disease and Neurodegenerative Disorders
Newly appointed advisors will further support AltPep’s research and clinical development of early detection and treatment alternatives for amyloid diseases
SEATTLE--(BUSINESS WIRE)-- AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the appointment of three new Advisory Board members: Paul Aisen, M.D., Sam Gandy, M.D., Ph.D., and Charlie Glabe, Ph.D. The advisory board now consists of world-renowned experts in discovery, preclinical and clinical research in Alzheimer’s disease and other neurodegenerative disorders.
“We are honored to have these esteemed and accomplished scientific and clinical leaders join AltPep’s Advisory Board,” said Valerie Daggett, Ph.D., Founder and CEO of AltPep. “These individuals have each made foundational contributions to the field of neurodegenerative diseases. Their depth of expertise, together with the contributions of our current advisors, will be critical in advancing the development of our unique platform for early detection and treatment of Alzheimer’s disease and other amyloid diseases.”
New Members of the AltPep Advisory Board
Paul Aisen, M.D. is Professor of Neurology at USC; Director, Alzheimer’s Therapeutic Research Institute; Co-Director, Clinical Core for the Alzheimer’s Disease Neuroimaging Initiative; and a member of the Alzheimer’s Clinical Trials Consortium Leadership Team. Dr. Aisen is a highly respected clinician who has led many Alzheimer’s disease clinical trials.
Sam Gandy, M.D., Ph.D. is Professor of Neurology and Psychiatry at Mount Sinai; Associate Director of the Mount Sinai Alzheimer’s Disease Research Center; and Past Chairman of the National Medical and Scientific Advisory Council of the Alzheimer’s Association. Dr. Gandy is a clinician and scientific expert in the cell biology and toxicity of fibrillar and oligomeric forms of the amyloid beta peptide (Aβ).
Charlie Glabe, Ph.D. is Professor of Molecular Biology and Biochemistry at University of California, Irvine. Dr. Glabe is an expert in the structure and aggregation of amyloid proteins, particularly Aβ, and was the first to synthesize and characterize Aβ. Dr. Glabe developed the widely used A11 antibody and made the seminal discovery that amyloidogenic toxic oligomers contain a common structure and common mechanism of pathogenesis.
The new advisors will join the existing advisory board members: Roger Armen, Ph.D., Sir Alan Ferscht, Ph.D., Michael Levitt, Ph.D., and Jeff Roh, M.D., MBA, M.Sc. See our board here.
About AltPep’s SOBA™ Diagnostics and SOBIN™ Therapeutics
SOBA diagnostics are highly sensitive, simple blood tests in development to aid in the diagnosis of amyloid diseases. SOBIN therapeutics are in development for use in concert with early detection to target and neutralize the toxic soluble oligomers associated with amyloid diseases.
AltPep has received Breakthrough Designation from the FDA for its SOBA-AD diagnostic for Alzheimer’s disease. The inclusion in the FDA Breakthrough Devices Program means that AltPep can expect prioritized review of the submission of the diagnostic test.
About AltPep Corporation
AltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers in order to both detect and neutralize them throughout disease progression. AltPep’s emphasis is on early, pre-symptomatic detection and treatment. Our lead programs focus on Alzheimer’s and Parkinson’s diseases, with other amyloid diseases on the horizon. AltPep’s goal is to change the course of these debilitating diseases that affect over a billion people around the globe.
Decades of scientific research by the Daggett Research Group at the University of Washington provided the foundation for AltPep’s innovative approach.
For more information, please visit altpep.com and follow us on LinkedIn.
Source: AltPep Corporation